<DOC>
	<DOCNO>NCT02984644</DOCNO>
	<brief_summary>To determine role plasma glucagon insulin rise endogenous glucose production ( EGP ) follow SGLT2 inhibition .</brief_summary>
	<brief_title>Paradoxical Stimulation Hepatic Glucose Production With Dapagliflozin</brief_title>
	<detailed_description>The increase plasma glucagon conc and/or decrease plasma insulin conc response glucosuria ( ) important signal ( ) responsible , least part , increase EGP , investigator anticipate derive primarily liver . Insulin glucagon powerful regulator HGP . Therefore , investigator anticipate , least part , increase HGP secondary rise plasma glucagon concentration decrease plasma insulin concentration response dapagliflozin-induced glucosuria account majority increase EGP NGT T2DM subject . This study define whether increase plasma glucagon and/or decrease plasma insulin trigger stimulate EGP . Eligible subject receive three 5-hour measurement endogenous glucose production ( EGP ) , biosynthesis new glucose , administration study drug 3-hour tracer equilibration period . Hepatic glucose production ( HGP ) , net release glucose liver , measure 5 hour drug administration allow sufficient time significant increase HGP baseline dapagliflozin administration ( 10 ) . In study 1 , HGP measure 5 hour dapagliflozin ( 10 mg ) placebo administration . This control study . The investigator expect observe `` paradoxical '' rise EGP follow dapagliflozin . Study 2 perform glucose clamp condition ( i.e . maintain plasma glucose concentration stable subject 's fasting level ) . This study define whether decline plasma glucose concentration trigger stimulate EGP . Study 3 perform pancreatic clamp condition ( maintain plasma glucagon insulin concentration constant basal level ) . This study define whether increase plasma glucagon and/or decrease plasma insulin trigger stimulate EGP . Subjects randomize 2:1 ratio ; 32 subject receive dapagliflozin 16 subject receive placebo . Each study perform separate day , 10-12 hour overnight fast within 1-2 week period . Following study 1-3 , subject return renal ( kidney ) MRI-measurement record kidney size .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>T2DM accord ADA criteriaHbA1C &lt; 8.0 % BMI = 2535 kg/m2 Subjects must good general health determine physical exam , medical history , blood chemistry , CBC , TSH , T4 , EKG urinanalysis Body weight stable ( Â± 3 lb ) precede three month Do participate excessively heavy exercise program Taking stable dose ( 3 month ) monotherapy combination therapy metformin and/or sulfonylurea Subjects take drug know affect glucose metabolism ( metformin sulfonylurea ) exclude Individuals evidence proliferative diabetic retinopathy , plasma creatinine &gt; 1.4 female &gt; 1.5 male , 24hour urine albumin excretion &gt; 300 mg exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>